What is GHRP-6

GHRP-6 is a synthetic hexapeptide belonging to the class of growth hormone secretagogues (GHS) studied in research for its profound ability to stimulate endogenous growth hormone and appetite. It is intended exclusively for research use.

Regarding its chemical identity, GHRP-6 has a molecular formula of C46H56N12O6 and a molecular weight of 873.0 g/mol. Its reported canonical sequence is His-D-Trp-Ala-Trp-D-Phe-Lys. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include GHRP-6.

Product for research use.

Mechanism of action of GHRP-6

GHRP-6 acts as an agonist at the ghrelin/growth hormone secretagogue receptor (GHSR). Binding to this receptor in the pituitary stimulates a massive, pulse-like release of Growth Hormone (GH). It also mimics ghrelin in the hypothalamus, triggering intense hunger signals.

Pharmacokinetics and pharmacodynamics of GHRP-6

GHRP-6 has a short half-life of approximately 15 to 30 minutes in plasma. Its rapid clearance necessitates frequent administration in research protocols to maintain elevated GH levels throughout a 24-hour cycle.

Scientific evidence on GHRP-6

The available evidence on GHRP-6 is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Studied for its potential in treating cachexia (muscle wasting), eating disorders, and growth hormone deficiencies. Preclinical models demonstrate dramatic increases in food intake, rapid weight gain, and accelerated tissue repair due to subsequent IGF-1 elevation.

GHRP-6 applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

GHRP-6 protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for GHRP-6, so no trial schemes or quantities are specified.

The presentations of this product (5MG & 10MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of GHRP-6

As a general guideline for laboratory handling, lyophilized peptides such as GHRP-6 are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 5MG & 10MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

GHRP-6 Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented GHRP-6 security profile

The documented safety information in open sources for GHRP-6 is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Commonly associated with intense hunger and potential insulin resistance if overused. Increased prolactin and cortisol levels can occur at high doses. The massive spike in GH can lead to temporary water retention and joint discomfort in animal models.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

GHRP-6 in a comparative context

Compared to GHRP-2 and Ipamorelin, GHRP-6 is notorious for causing the most intense hunger stimulation (gastric motility). It causes a moderate increase in cortisol and prolactin, placing it between the highly specific Ipamorelin and the highly potent GHRP-2.

History and development of GHRP-6

Developed in the late 1980s as one of the first synthetic, non-natural peptides capable of releasing GH. It was created through structure-activity relationship studies to find molecules that could bypass the standard GHRH pathway.